BM
ALXN

Bill Miller’s Alexion Pharmaceuticals ALXN Stock Holding History

Bill Miller’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-388,380
Closed -$42M – 95
2019
Q4 		$42M Sell
388,380
-60,400
-13% -$6.46M 1.49% 34
2019
Q3 		$44M Hold
448,780
– – 1.77% 29
2019
Q2 		$58.8M Buy
448,780
+1,100
+0.2% +$142K 2.24% 23
2019
Q1 		$60.5M Sell
447,680
-455
-0.1% -$56.6K 2.4% 21
2018
Q4 		$43.6M Sell
448,135
-690
-0.2% -$81.6K 1.98% 25
2018
Q3 		$62.4M Buy
448,825
+6,480
+1% +$813K 2.01% 23
2018
Q2 		$54.9M Buy
442,345
+21,280
+5% +$2.49M 2.05% 26
2018
Q1 		$46.9M Sell
421,065
-15,800
-4% -$1.89M 1.96% 22
2017
Q4 		$52.2M Sell
436,865
-7,560
-2% -$921K 2.22% 23
2017
Q3 		$62.3M Sell
444,425
-6,300
-1% -$856K 2.68% 19
2017
Q2 		$54.8M Buy
450,725
+92,025
+26% +$10.7M 2.22% 21
2017
Q1 		$43.5M Buy
358,700
+258,990
+260% +$33.4M 1.91% 23
2016
Q4 		$12.2M Buy
+99,710
New +$12.2M 0.54% 35

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bill Miller's ALXN Position: Q1 2020 in Review

Bill Miller sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 388,380 shares — an estimated $42M sold.

Bill Miller first reported a position in ALXN in Q4 2016 and held it in 13 quarters. The position peaked at $62.4M in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Bill Miller reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Bill Miller sold 388,380 Alexion Pharmaceuticals shares in Q1 2020, an estimated $42M.
  • Bill Miller first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 13 quarters.
  • Bill Miller's Alexion Pharmaceuticals position peaked at $62.4M in Q3 2018.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Miller Value Partners's 13F filing for Q1 2020, filed 15 May 2020.